AtaiBeckley Inc. (ATAI)
NASDAQ
Delayed Data
Oct 22, 2026, 01:30 PM
Day's Range
0.641852 wk Range
0.6000Profile - ATAI - AtaiBeckley Inc.
Profile
Mic Code
XNMS
Sector
Healthcare
Industry
Biotechnology
Employees
99
AtaiBeckley Inc. is a clinical-stage biopharmaceutical company focused on developing mental health treatments. The company concentrates on rapid-acting, durable, and convenient therapies designed to address difficult-to-treat psychiatric conditions, including depression, treatment-resistant depression, social anxiety disorder, and other central nervous system disorders. Its current pipeline includes investigational programs based on psychedelic-inspired and neuroplasticity-driven compounds, developed through internal research and strategic collaborations. AtaiBeckley Inc. also works across discovery, clinical development, and potential commercialization activities, reflecting its role in advancing new therapeutic options within the mental health and neuroscience markets. Headquartered in New York, AtaiBeckley Inc. operates as part of the broader biotechnology and pharmaceutical sector, where it is known for targeting unmet needs in mental health care with a specialized, research-focused portfolio.
Profile Details
Type
Common Stock
Address
250 West 34th Street
City
New York
State
NY
Zip
10119
Country
United States
Phone
332 282 0507
Key Executives - ATAI - AtaiBeckley Inc.
Key executives
Cross Listings - ATAI - AtaiBeckley Inc.
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
